Endast för hälso-och sjukvårdspersonal

Produktresumé för våra godkända läkemedel på FASS:  Breyanzi® (lisokabtagen-maraleucel)

Highlights of Transform Study – Breyanzi in R/R LBCL

Duration: 12 minutes

A quick guide to second line treatment and how Breyanzi compares to earlier standard of care in aggressive B-cell lymphoma. Disease Area Specialist Nora Liske gives a short study overview as well as key efficacy and safety outcomes.

Related videos

Nytt nationellt vårdprogram aggressivt B-cellslymfom – fokus på CAR-T

From Clinical Study To Clinical Practice with CAR-T

News

Learn about current topics in hematology, such as new research data, news from events, congresses and more.

Education

Find past and upcoming educational events and access learning tools such as webinars, training videos and expert interviews.

HE-SE-2500027 May 2025 video/ 2009-SE-2500035 01/2026